For at reducere risikoen for resistens hos patienter som får adefovirdipivoxil- monoterapi, bør en justering af behandlingen overvejes, hvis serum- HBV- DNA forbliver over 1. 000 kopier/ ml efter et års behandling eller længere.
In order to reduce the risk of resistance in patients receiving adefovir dipivoxil monotherapy, a modification of treatment should be considered if serum HBV DNA remains above 1,000 copies/ ml at or beyond 1 year of treatment.